Allogeneic HCT Using Uniform Conditioning Regimen Regardless of Donors (MS, MU, or HF) for AML in Remission

UnknownOBSERVATIONAL
Enrollment

110

Participants

Timeline

Start Date

April 1, 2017

Primary Completion Date

March 30, 2021

Study Completion Date

March 30, 2021

Conditions
Acute Myeloid Leukemia
Interventions
PROCEDURE

allogeneic hematopoietic cell transplantation

perform allogeneic hematopoietic cell transplantation (HCT) using conditioning regimen of busulfan, fludarabine, and antithymocyte globulin

Trial Locations (1)

Unknown

RECRUITING

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Korea Research Institute of Bioscience & Biotechnology

OTHER_GOV

lead

Asan Medical Center

OTHER

NCT03337568 - Allogeneic HCT Using Uniform Conditioning Regimen Regardless of Donors (MS, MU, or HF) for AML in Remission | Biotech Hunter | Biotech Hunter